path4107-sup-0001-FigureS1.pdfPDF document134K Figure S1. (A) Western blot showing HIF-2α down-regulation in 786-O cells with three different siHIF-2α (siHIF-2α #1, siHIF-2α #2, siHIF-2α #3) to exclude off target effects for changed PTPRJ expression. (B) Increased PTPRJ mRNA levels in 786-O cells and (C) in RCC4 cells after silencing of HIF-2α with siHIF-2α #2.
path4107-sup-0002-FigureS2.pdfPDF document59K Figure S2. Kaplan–Meier plot of the overall survival of ccRCC patients with organ-confined (stage pT1/pT2) and locally advanced tumours (pT3/pT4).
path4107-sup-0003-FigureS3.pdfPDF document86K Figure S3. (A) Western blot showing PTPRJ down-regulation in HK2 cells 72 h after transfection. (B) Proliferation of HK2 cells 24, 48, 72, and 96 h after transfection of siPTPRJ and siScrambled (control).
path4107-sup-0004-TableS1.pdfPDF document43K Table S1. Clinico-pathological features and VHL mutation status of 17 ccRCC samples analysed for PTPRJ mRNA expression by qRT-PCR.
path4107-sup-0005-TableS2.pdfPDF document66K Table S2. siRNA sequences.
path4107-sup-0006-TableS3.pdfapplication/unknown61K Table S3. Location of the five HREs and three reverse HREs in the putative PTPRJ promoter.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.